MindWalk Holdings (HYFT) Profit After Tax (2020 - 2026)
MindWalk Holdings (HYFT) posted quarterly Profit After Tax of -$3087.3 for Q2 2026, up 75.05% year-over-year from -$1763.6 in Q2 2025, and up 99.89% quarter-over-quarter from -$2.8 million in Q1 2026.
MindWalk Holdings (HYFT) Profit After Tax (2020 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported Profit After Tax for 7 consecutive years, with -$3087.3 the latest figure, recorded in Q2 2026.
- In Q2 2026, Profit After Tax rose 75.05% year-over-year to -$3087.3; the TTM figure through Apr 2026 stood at -$5.1 million (up 99.82% YoY), while the FY2026 annual figure was -$11.0 million, up 53.7% from the prior year.
- Profit After Tax advanced to -$3087.3 in Q2 2026 per HYFT's latest filing, from -$2.8 million in the prior quarter.
- Across five years, Profit After Tax topped out at -$2910.4 in Q3 2025 and bottomed at -$2.9 billion in Q3 2024.
- Historically, Profit After Tax has averaged -$407.5 million across 5 years, with a median of -$3.9 million in 2022.
- Annual changes were most pronounced in 2022 — Profit After Tax sank 277296.2% — and 2025, when it soared 100.0%.
- MindWalk Holdings' Profit After Tax stood at -$5.5 million in 2022, then slumped by 32000.67% to -$1.8 billion in 2023, then soared by 99.89% to -$1.9 million in 2024, then fell by 23.2% to -$2.3 million in 2025, then jumped by 99.87% to -$3087.3 in 2026.
- Business Quant data shows HYFT's Profit After Tax at -$3087.3 in Q2 2026, -$2.8 million in Q1 2026, and -$2.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -290.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -3,087.27 |
| Jan 31, 2026 | -2.83 Mn |
| Oct 31, 2025 | -2.30 Mn |
| Jul 31, 2025 | -2,910.41 |
| Apr 30, 2025 | -12,375.05 |
| Jan 31, 2025 | -15.16 Mn |
| Oct 31, 2024 | -1.87 Mn |
| Jul 31, 2024 | -2.92 Bn |
| Apr 30, 2024 | -15.34 Mn |
| Jan 31, 2024 | -1.98 Mn |
| Oct 31, 2023 | -1.78 Bn |
| Jul 31, 2023 | -2.56 Bn |
| Apr 30, 2023 | -3.79 Mn |
| Jan 31, 2023 | -15.96 Mn |
| Oct 31, 2022 | -5.53 Mn |
| Jul 31, 2022 | -7.29 Mn |
| Apr 30, 2022 | -3.97 Mn |
| Jan 31, 2022 | -3.02 Mn |
| Oct 31, 2021 | -3,984.35 |
| Jul 31, 2021 | -2,629.17 |